PDCOS
MCID: PDC001
MIFTS: 42

Podoconiosis (PDCOS)

Categories: Immune diseases

Aliases & Classifications for Podoconiosis

MalaCards integrated aliases for Podoconiosis:

Name: Podoconiosis 57 12 15 17 70
Podoconiosis, Susceptibility to 57 13
Nonfilarial Elephantiasis of Lower Legs, Susceptibility to 57
Endemic Nonfilarial Elephantiasis, Susceptibility to 57
Lymphostatic Verrucosis, Susceptibility to 57
Nonfilarial Elephantiasis of Lower Legs 57
Endemic Non-Filarial Elephantiasis 70
Endemic Nonfilarial Elephantiasis 57
Lymphostatic Verrucosis 57
Elephantiasis 44
Pdcos 57

Classifications:



External Ids:

Disease Ontology 12 DOID:0050138
OMIM® 57 614590
MeSH 44 D004604
UMLS 70 C1280469 C3494152

Summaries for Podoconiosis

OMIM® : 57 Podoconiosis, or endemic nonfilarial elephantiasis, is a noninfectious geochemical disease characterized by edema of the foot and lower leg that progresses to severe elephantiasis. It is a chronic and debilitating disorder that is a public health problem in at least 10 countries in tropical Africa, Central America, and northern India. Podoconiosis occurs among subsistence farmers and other occupational groups whose feet are exposed over many years to red clay soil derived from alkalic volcanic rock. However, podoconiosis develops only in a subgroup of exposed people, and studies have shown familial clustering with high heritability (summary by Davey et al. (2007) and Tekola Ayele et al. (2012)). (614590) (Updated 05-Apr-2021)

MalaCards based summary : Podoconiosis, also known as podoconiosis, susceptibility to, is related to elephantiasis and leishmaniasis. An important gene associated with Podoconiosis is PDCOS (Podoconiosis, Susceptibility To), and among its related pathways/superpathways are Actin Nucleation by ARP-WASP Complex and TCR Signaling (Qiagen). The drugs Glycerol and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include lower extremities, skin and liver.

Disease Ontology : 12 An elephantiasis that is characterized by lymphadema located in the lower extremities caused by a genetically determined abnormal inflammatory reaction to mineral particles in irritant red clay soils derived from volcanic deposits.

Wikipedia : 73 Podoconiosis, also known as nonfilarial elephantiasis, is a disease of the lymphatic vessels of the... more...

Related Diseases for Podoconiosis

Diseases related to Podoconiosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 elephantiasis 31.1 TVP23C HLA-DQA2 CDRT4
2 leishmaniasis 30.0 HLA-DRB1 HLA-DQB1 HLA-DQA1
3 trachoma 29.8 HLA-DRB1 HLA-DQB1
4 graves' disease 29.7 HLA-DRB1 HLA-DQB1 HLA-DQA1
5 juvenile rheumatoid arthritis 29.7 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 calcinosis 29.4 HLA-DRB1 HLA-DQB1 HLA-DQA1
7 loiasis 10.9
8 filarial elephantiasis 10.7
9 filariasis 10.5
10 hereditary lymphedema i 10.5
11 neurofibromatosis 10.4
12 leprosy 3 10.3
13 hansen's disease 10.3
14 venous insufficiency 10.2
15 lymphogranuloma venereum 10.2
16 neurofibroma 10.2
17 diamond-blackfan anemia 3 10.2 HLA-DQA2 HLA-DQA1
18 achalasia, familial esophageal 10.2 HLA-DQB1 HLA-DQA1
19 hydrocele 10.2
20 disease by infectious agent 10.2
21 shrimp allergy 10.2 HLA-DQB1 HLA-DQA1
22 lymphangiosarcoma 10.2
23 cellulitis 10.2
24 congestive heart failure 10.2
25 congenital toxoplasmosis 10.1 HLA-DQB1 HLA-DQA1
26 yaws 10.1
27 erysipelas 10.1
28 primary lymphedema 10.1
29 leptin deficiency or dysfunction 10.1
30 chronic venous insufficiency 10.1
31 granuloma inguinale 10.1
32 eosinophilia-myalgia syndrome 10.1 HLA-DRB1 HLA-DQA1
33 berylliosis 10.1 HLA-DRB1 CDRT4
34 hidradenitis suppurativa 10.1
35 hidradenitis 10.1
36 lymphangiectasis 10.1
37 sympathetic ophthalmia 10.1 HLA-DRB1 HLA-DQA1
38 cervical dystonia 10.1 HLA-DQB1 HLA-DQA1
39 histoplasmosis 10.1 HLA-DRB1 HLA-DQA1
40 limbic encephalitis with lgi1 antibodies 10.1 HLA-DRB1 HLA-DQB1
41 type 1 diabetes mellitus 2 10.1 HLA-DQB1 HLA-DQA1
42 autoimmune polyglandular syndrome type 3 10.1 HLA-DRB1 HLA-DQB1
43 idiopathic hypersomnia 10.1 HLA-DRB1 HLA-DQB1
44 hypersomnia 10.1 HLA-DRB1 HLA-DQB1
45 narcolepsy 2 10.1 HLA-DRB1 HLA-DQB1
46 htlv-1 associated myelopathy/tropical spastic paraparesis 10.1 HLA-DRB1 HLA-DQB1
47 latent autoimmune diabetes in adults 10.1 HLA-DRB1 HLA-DQB1
48 occupational asthma 10.1 HLA-DRB1 HLA-DQB1
49 recurrent respiratory papillomatosis 10.1 HLA-DRB1 HLA-DQB1
50 beryllium disease 10.1 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Podoconiosis:



Diseases related to Podoconiosis

Symptoms & Phenotypes for Podoconiosis

Clinical features from OMIM®:

614590 (Updated 05-Apr-2021)

Drugs & Therapeutics for Podoconiosis

Drugs for Podoconiosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycerol Approved, Investigational Phase 3 56-81-5 753
2
Petrolatum Approved, Investigational Phase 3 8009-03-8
3
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
4
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
7 Sodium hypochlorite Phase 3
8 Protective Agents Phase 3
9 Eusol Phase 3
10 Antimalarials Phase 3
11 Milbemycin Phase 3
12 Citrate Phase 3
13
Piperazine Approved, Vet_approved 110-85-0 4837
14
Mebendazole Approved, Vet_approved 31431-39-7 4030
15
Permethrin Approved, Investigational 52645-53-1 40326
16 Chelating Agents
17 Anticoagulants
18 DMP 777 157341-41-8
19 Piperazine citrate
20 Calcium, Dietary
21 Liver Extracts
22
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
2 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
6 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
7 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
8 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
9 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
10 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
11 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Enrolling by invitation NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
12 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
13 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
14 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
15 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
18 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
19 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
20 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
21 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
22 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
23 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
24 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
25 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
26 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
27 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
28 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
29 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
30 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
31 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
32 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
33 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
34 Research for Elimination of Human Filariasis Completed NCT00145223
35 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
36 Exhaled NO Testing in Filariasis Completed NCT01628497
37 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
38 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Active, not recruiting NCT04258670
39 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
40 Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches Terminated NCT01939431
41 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Podoconiosis

Cochrane evidence based reviews: elephantiasis

Genetic Tests for Podoconiosis

Anatomical Context for Podoconiosis

The Foundational Model of Anatomy Ontology organs/tissues related to Podoconiosis:

19
Lower Extremities

MalaCards organs/tissues related to Podoconiosis:

40
Skin, Liver, Lymph Node

Publications for Podoconiosis

Articles related to Podoconiosis:

(show top 50) (show all 191)
# Title Authors PMID Year
1
HLA class II locus and susceptibility to podoconiosis. 57 61
22455414 2012
2
Images in clinical medicine. Podoconiosis. 57 61
21428762 2011
3
Podoconiosis: a tropical model for gene-environment interactions? 57 61
16884751 2007
4
Pre-elephantiasic stage of endemic nonfilarial elephantiasis of lower legs: "podoconiosis". 57 61
6464174 1984
5
The association of endemic elephantiasis of the lower legs in East Africa with soil derived from volcanic rocks. 57
1006757 1976
6
A possible genetic factor in non-filarial elephantiasis of the lower legs. 57
4670473 1972
7
A family-based intervention for prevention and self-management of disabilities due to leprosy, podoconiosis and lymphatic filariasis in Ethiopia: A proof of concept study. 61
33600453 2021
8
Replication of HLA class II locus association with susceptibility to podoconiosis in three Ethiopian ethnic groups. 61
33558538 2021
9
Rapid ethical appraisal of stakeholder views on research prior to undertaking immunopathogenesis studies on podoconiosis in northeast Ethiopia during a period of social instability. 61
33570141 2021
10
Surgical debulking of podoconiosis nodules and its impact on quality of life in Ethiopia. 61
33481805 2021
11
With Bare Feet in the Soil: Podoconiosis, a Neglected Cause of Tropical Lymphoedema. 61
32101870 2021
12
Using ethnographic film in tackling podoconiosis. 61
33211884 2020
13
An exploration of family quality of life in persons with leprosy-, lymphatic filariasis- and podoconiosis-related disabilities and their family members in Ethiopia. 61
33169139 2020
14
Economic assessment of a community-based care package for people with lower limb disorder caused by lymphatic filariasis, podoconiosis and leprosy in Ethiopia. 61
33169165 2020
15
A cross-sectional study to evaluate depression and quality of life among patients with lymphoedema due to podoconiosis, lymphatic filariasis and leprosy. 61
33190154 2020
16
Developing and validating a clinical algorithm for the diagnosis of podoconiosis. 61
33174588 2020
17
Addition of Lymphatic Stimulating Self-Care Practices Reduces Acute Attacks among People Affected by Moderate and Severe Lower-Limb Lymphedema in Ethiopia, a Cluster Randomized Controlled Trial. 61
33348721 2020
18
Linking soils and human health: geospatial analysis of ground-sampled soil data in relation to community-level podoconiosis data in North West Cameroon. 61
33216129 2020
19
Developing consensus of evidence to target case finding surveys for podoconiosis: a potentially forgotten disease in India. 61
33169156 2020
20
Severely stigmatised skin neglected tropical diseases: a protocol for social science engagement. 61
33324991 2020
21
Multiplexed gene expression analysis of HLA class II-associated podoconiosis implicates chronic immune activation in its pathogenesis. 61
33099652 2020
22
'Far from the views of decision-makers': podoconiosis instruction at medical schools across endemic countries in Africa. 61
33169131 2020
23
Individual and familial characteristics of patients with podoconiosis attending a clinic in Musanze District, Rwanda: A retrospective study. 61
33169149 2020
24
Podoconiosis: key priorities for research and implementation. 61
33169167 2020
25
A cross-sectional survey to assess the risk factors associated with stigmatizing attitudes towards patients with podoconiosis among rural youth in southern Ethiopia. 61
33169168 2020
26
Clinical, haematological and biochemical profiling of podoconiosis lymphoedema patients prior to their involvement in a clinical trial in the Northwest Region of Cameroon. 61
33258944 2020
27
Excess mortality among people with podoconiosis: secondary analysis of two Ethiopian cohorts. 61
33236119 2020
28
High levels of depressive symptoms among people with lower limb lymphoedema in Rwanda: a cross-sectional study. 61
33220054 2020
29
Podoconiosis, skin-NTDs and global health. 61
33169171 2020
30
Podoconiosis in Rwanda: Knowledge, attitudes and practices among health professionals and environmental officers. 61
33027253 2020
31
EnDPoINT: protocol for an implementation research study to integrate a holistic package of physical health, mental health and psychosocial care for podoconiosis, lymphatic filariasis and leprosy into routine health services in Ethiopia. 61
33060082 2020
32
Predicting the environmental suitability and population at risk of podoconiosis in Africa. 61
32853202 2020
33
Intra-Rater Reliability and Agreement of the Indurometer When Used to Assess Mid-Calf Tissue Compressibility Among People Affected by Moderate to Severe Lymphedema in Bangladesh and Ethiopia. 61
31859599 2020
34
Is vitiligo associated with wearing plastic shoes in a podoconiosis endemic region of Ethiopia? 61
32614792 2020
35
The health and economic burden of podoconiosis in Ethiopia. 61
32055853 2020
36
The impact of leprosy, podoconiosis and lymphatic filariasis on family quality of life: A qualitative study in Northwest Ethiopia. 61
32155158 2020
37
Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia. 61
32126081 2020
38
The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. 61
32228663 2020
39
Magnitude of Podoconiosis and Its Associated Factors among an Adult Population in Waghmra Zone, Ethiopia: A Cross-Sectional Study. 61
32832556 2020
40
Epidemiology of podoconiosis in Ethiopia: a systematic review and meta-analysis protocol. 61
31915168 2020
41
Gender-related factors affecting health seeking for neglected tropical diseases: findings from a qualitative study in Ethiopia. 61
31830026 2019
42
Mapping the global distribution of podoconiosis: Applying an evidence consensus approach. 61
31790408 2019
43
Dr E W Price, the discoverer of podoconiosis. 61
31735101 2019
44
Picturing health: podoconiosis-stepping out of neglect. 61
32534625 2019
45
Cost-effectiveness and social outcomes of a community-based treatment for podoconiosis lymphoedema in the East Gojjam zone, Ethiopia. 61
31644556 2019
46
Comparison of Staging Systems to Assess Lymphedema Caused by Cancer Therapies, Lymphatic Filariasis, and Podoconiosis. 61
30789319 2019
47
An Enhanced Self-Care Protocol for People Affected by Moderate to Severe Lymphedema. 61
31487887 2019
48
Depressive Symptoms Amongst People with Podoconiosis and Lower Limb Lymphoedema of Other Cause in Cameroon: A Cross-Sectional Study. 61
31323942 2019
49
The impact of acute adenolymphangitis in podoconiosis on caregivers: A case study in Wayu Tuka woreda, Oromia, Western Ethiopia. 'If she was healthy, I would be free.' 61
31283763 2019
50
Geographical distribution and prevalence of podoconiosis in Rwanda: a cross-sectional country-wide survey. 61
30926303 2019

Variations for Podoconiosis

Expression for Podoconiosis

Search GEO for disease gene expression data for Podoconiosis.

Pathways for Podoconiosis

Pathways related to Podoconiosis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
2
Show member pathways
12.7 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
3
Show member pathways
12.64 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
4
Show member pathways
12.62 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 12.59 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
6
Show member pathways
12.44 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
7
Show member pathways
12.41 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
8
Show member pathways
12.36 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
9
Show member pathways
12.24 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
10
Show member pathways
12.2 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
11 12.18 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
12
Show member pathways
12.1 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
13 12.07 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
14
Show member pathways
12.03 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
15 11.96 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
16 11.91 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
17 11.74 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
18
Show member pathways
11.74 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
19 11.68 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
20 11.62 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
21 11.54 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
22 11.43 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
23 11.11 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
24
Show member pathways
10.88 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1

GO Terms for Podoconiosis

Cellular components related to Podoconiosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.15 TVP23C SLC24A5 ITFG1 HLA-DRB1 HLA-DQB1 HLA-DQA2
2 endosome GO:0005768 9.83 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
3 Golgi membrane GO:0000139 9.81 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
4 lysosome GO:0005764 9.78 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 lysosomal membrane GO:0005765 9.76 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
6 endosome membrane GO:0010008 9.73 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
7 endocytic vesicle membrane GO:0030666 9.71 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
8 ER to Golgi transport vesicle membrane GO:0012507 9.67 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
9 transport vesicle membrane GO:0030658 9.62 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
10 clathrin-coated endocytic vesicle membrane GO:0030669 9.56 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
11 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.46 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
12 trans-Golgi network membrane GO:0032588 9.35 SLC24A5 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
13 MHC class II protein complex GO:0042613 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1

Biological processes related to Podoconiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
2 adaptive immune response GO:0002250 9.73 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
3 T cell receptor signaling pathway GO:0050852 9.62 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.56 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 melanocyte differentiation GO:0030318 9.46 SLC24A5 EDNRB
6 interferon-gamma-mediated signaling pathway GO:0060333 9.46 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
7 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DRB1 HLA-DQB1
8 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.37 HLA-DRB1 HLA-DQB1
9 antigen processing and presentation GO:0019882 9.26 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1
10 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1

Molecular functions related to Podoconiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
2 MHC class II receptor activity GO:0032395 8.92 HLA-DRB1 HLA-DQB1 HLA-DQA2 HLA-DQA1

Sources for Podoconiosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....